Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults With Cervical Dystonia: Results From the Open-label Extension of a Phase 2 Trial

被引：0
|
作者：
Jankovic, Joseph [1 ]
Oh, Chad [2 ]
Liu, Yan [2 ]
Abdul-Musawir, Najeebah [2 ]
Comella, Cynthia [3 ]
机构：
[1] Baylor Coll Med, St Lukes Med Ctr, Dept Neurol, Parkinsons Dis Ctr & Movement Disorders Clin, McNair Campus,7200 Cambridge St,Suite 9A, Houston, TX USA
[2] AEON Biopharma Inc, Irvine, CA USA
[3] Rush Univ, Med Ctr, Chicago, IL USA
来源：
TOXICON | 2024年 / 237卷
关键词：
Cervical dystonia; Type A botulinum toxins; PrabotulinumtoxinA; Torticollis; Dyskinesias; Neurologic manifestations;
D O I：
10.1016/j.toxicon.2024.107415
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：36 / 37
页数：3
相关论文
共 50 条
  • [1] A Phase 2, Double-blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ABP-450 (PrabotulinumtoxinA) in Adults with Isolated Cervical Dystonia
    Jankovic, J.
    Oh, C.
    Liu, Y.
    Comella, C.
    MOVEMENT DISORDERS, 2023, 38 : S349 - S349
  • [2] ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY
    Cohen, S.
    Pablos, J. L.
    Wang, H.
    Mueller, G. A.
    Kivitz, A.
    Matsumoto, A.
    Krishnan, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 834 - 835
  • [3] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [4] Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial
    Craig, T. J.
    Reshef, A.
    Lumry, W. R.
    Saguer, I. Martinez
    Jacobs, J. S.
    Yang, W. H.
    Aygoren-Pursun, E.
    Keith, P. K.
    Busse, P.
    Magerl, M.
    Feuersenger, H.
    Bica, M. A.
    Glassman, F.
    Pragst, I.
    Levy, D. S.
    ALLERGOLOGIE, 2023, 46 (08) : 560 - 561
  • [5] An Open-Label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel in Cervical Dystonia
    Fox, Susan H.
    Swan, Matthew
    Jinnah, Hyder A.
    Freitas, Maria E. T.
    Oliveira, Lais M.
    Al-Shorafat, Duha
    Fernandez, Hubert H.
    Kompoliti, Katie
    Comella, Cynthia
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2021, 8 (05): : 743 - 749
  • [6] Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase
    Weisshaar, E.
    Szepietowski, J. C.
    Bernhard, J. D.
    Hait, H.
    Legat, F. J.
    Nattkemper, L.
    Reich, A.
    Sadoghi, B.
    Sciascia, T. R.
    Zeidler, C.
    Yosipovitch, G.
    Staender, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (03) : 453 - 461
  • [7] Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: Results of a phase 2 randomized controlled trial with an open-label extension phase
    Weisshaar, Elke
    Szepietowski, Jacek C.
    Sciascia, Thomas R.
    Yosipovitch, Gil
    Staender, Sonja
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB72 - AB72
  • [8] Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
    Pavel, Marianne
    Benavent, Marta
    Perros, Petros
    Srirajaskanthan, Raj
    Warner, Richard R. P.
    Kulke, Matthew H.
    Anthony, Lowell B.
    Kunz, Pamela L.
    Hoersch, Dieter
    Lapuerta, Pablo
    Fleming, Rosanna
    Gross, David J.
    PANCREAS, 2018, 47 (03) : 350 - 350
  • [9] Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
    Pavel, M.
    Benavent, M.
    Perros, P.
    Srirajaskanthan, R.
    Warner, R. R. P.
    Kulke, M. H.
    Anthony, L. B.
    Kunz, P.
    Hoersch, D.
    Lapuerta, P.
    Fleming, R.
    Gross, D.
    NEUROENDOCRINOLOGY, 2017, 105 : 205 - 205
  • [10] A Phase 3, Open-Label, Multicenter Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia
    Slawek, Jaroslaw
    McAllister, Peter
    Paus, Sebastian
    Truong, Daniel
    Gross, Todd M.
    Rubio, Roman G.
    Kesslak, Pat
    Vitarella, Domenico
    TOXICON, 2022, 214 : S50 - S50
12345